Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Levosimendan (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms REFALS
- Sponsors Orion
- 04 Feb 2019 According to an Orion media release, Professor Merit Cudkowicz, Director of the Healey Center for ALS at Masachusetts General Hospital is the lead investigator of this study.
- 04 Feb 2019 According to an Orion media release, patient enrolment is expected to continue until early summer 2019.
- 06 Jul 2018 Status changed from not yet recruiting to recruiting, as reported in the Orion Pharma media release.